About
Ensho Therapeutics is a clinical-stage biopharmaceutical company developing an oral small molecule α4β7 integrin inhibitor, NSHO-101, aimed at treating inflammatory bowel disease by providing a convenient alternative to biologic therapies.
Explore Ensho Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.